Out of 20 FGFR2-rearranged patients with recurrent or advanced iCCA, 18 underwent first-line chemotherapy (cisplatin/gemcitabine or cisplatin/S-1) with a progression-free survival (PFS) in line with known data (8.9 months compared to the 8.0 months of the ABC-02 trial (5); however, 13 of them had subsequent anti-FGFR2 therapies, obtaining an OS of 38.8 months. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.